Search research articles
Contact Us
Filters
Showing results (31-40 of 38) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 38 results.
Journal of Cancer Research and Clinical Oncology
|
January 1, 1991
Improvement of local control by regional hyperthermia combined with systemic chemotherapy (ifosfamide plus etoposide) in advanced sarcomas: updated report on 65 patients
R D Issels, J Mittermüller, A Gerl, et al.
British Journal of Haematology
|
December 19, 1998
Poor response rate to a continuous schedule of Amifostine therapy for 'low/intermediate risk' myelodysplastic patients
D T Bowen, C Denzlinger, W Brugger, et al.
Anticancer Research
|
August 10, 2002
Potentially therapeutically relevant differences of antisense oligonucleotide uptake in CD34+ hematopoietic stem cells, leukemic blasts and cancer cells from patients
G Seitz, G Kohler, M Nehmzow, et al.
Infection
|
April 29, 1999
Human parvovirus B19-associated disease in bone marrow transplantation
M Schleuning, G Jäger, E Holler, et al.
Leukemia Research
|
June 22, 1999
Functional analysis of P-glycoprotein and multidrug resistance associated protein related multidrug resistance in AML-blasts
D Brügger, H Herbart, V Gekeler, et al.
Leukemia
|
August 5, 2005
Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups
S Amadori, S Suciu, R Stasi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 5, 2020
CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in patients with R1 resection of pancreatic cancer - Final results
M Sinn, T Liersch, H Riess, et al.
ESMO Open
|
May 14, 2024
Evaluation of the inflammation-based modified Glasgow Prognostic Score (mGPS) as a prognostic and predictive biomarker in patients with metastatic colorectal cancer receiving first-line chemotherapy: a post hoc analysis of the randomized phase III XELAVIRI trial (AIO KRK0110)
M Boukovala, D P Modest, I Ricard, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 38) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 38 results.
Journal of Cancer Research and Clinical Oncology
|
January 1, 1991
Improvement of local control by regional hyperthermia combined with systemic chemotherapy (ifosfamide plus etoposide) in advanced sarcomas: updated report on 65 patients
R D Issels, J Mittermüller, A Gerl, et al.
British Journal of Haematology
|
December 19, 1998
Poor response rate to a continuous schedule of Amifostine therapy for 'low/intermediate risk' myelodysplastic patients
D T Bowen, C Denzlinger, W Brugger, et al.
Anticancer Research
|
August 10, 2002
Potentially therapeutically relevant differences of antisense oligonucleotide uptake in CD34+ hematopoietic stem cells, leukemic blasts and cancer cells from patients
G Seitz, G Kohler, M Nehmzow, et al.
Infection
|
April 29, 1999
Human parvovirus B19-associated disease in bone marrow transplantation
M Schleuning, G Jäger, E Holler, et al.
Leukemia Research
|
June 22, 1999
Functional analysis of P-glycoprotein and multidrug resistance associated protein related multidrug resistance in AML-blasts
D Brügger, H Herbart, V Gekeler, et al.
Leukemia
|
August 5, 2005
Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups
S Amadori, S Suciu, R Stasi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 5, 2020
CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in patients with R1 resection of pancreatic cancer - Final results
M Sinn, T Liersch, H Riess, et al.
ESMO Open
|
May 14, 2024
Evaluation of the inflammation-based modified Glasgow Prognostic Score (mGPS) as a prognostic and predictive biomarker in patients with metastatic colorectal cancer receiving first-line chemotherapy: a post hoc analysis of the randomized phase III XELAVIRI trial (AIO KRK0110)
M Boukovala, D P Modest, I Ricard, et al.
Page
of 4